
Imago BioSciences Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from Imago BioSciences Inc
Access all reports
Imago BioSciences, Inc. is a clinical stage biopharmaceutical company focused on discovering and developing small molecule product candidates that target lysine-specific demethylase 1 (LSD1), an enzyme used in the production of blood cells in the bone marrow. We are conducting clinical trials for bomedemstat which is being developed as a treatment for myeloproliferative neoplasms (MPNs).
Latest articles
)
Robert G. Hagstrom: Darwinian Investing and Multidisciplinary Wisdom
Robert G. Hagstrom, author of The Warren Buffett Way, explores how interdisciplinary thinking shapes his investing, from Adler's reading to Darwinian markets.
7 Feb 2025
)
Quartr Brings Stories Behind the Numbers to Light
Quartr simplifies access to IR material and puts qualitative insights and company narratives front and center.
3 Feb 2025
)
The Evolution of the IRO Role: Staying Informed and Strategic With Quartr Pro
Staying informed is critical for IROs. Quartr Pro simplifies gathering market insights and narrative positioning with unprecedented speed and precision.
3 Feb 2025
Ticker symbol
IMGO
Country
🇺🇸 United States